Resveratrol: An assessment of its dose response an introduction

Human and Experimental Toxicology

Volumn 29, Issue 12, 2010, Pages 977-979

  Calabrese, Edward J ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; RESVERATROL;

DOSE RESPONSE; FACTUAL DATABASE; GENOTOXICITY; HORMESIS; IONIZING RADIATION; MEDICAL RESEARCH; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; REPRODUCIBILITY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; STILBENES;

EID: 78649919277     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327110383623     Document Type: Note

References (19)

1. Mochly-Rosen D., Zakhari S. Focus on: the cardiovascular system what did we learn from the French (paradox)? Alcoh Res Health 2010 ; 33: 76-86.
2. Ramprasath VR, Jones PJH. Anti-atherogenic effects of resveratrol. Eur J Clin Nutr 2010 ; 64: 660-668.
3. Tosun I., Inkaya AN Resveratrol as a health and disease benefit agent. Food Rev Intern 2010 ; 26: 85-101.
4. Sun AY, Wang Q., Simonyi A., and Sun GY Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol Neurobiol 2010 ; 41: 375-383.
5. Yusuf N., Nasti TH, Meleth S., and Elmets CA Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis. Mol Carcinog 2009 ; 48: 713-723.
6. Alfaras I., Juan ME, and Planas JM Trans-resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. J Agri Food Chem. 2010 ; 58: 8104-8110.
7. Imai SI A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol Res 2010 ; 62: 42-47.
8. Calabrese EJ BELLE: an evolving legacy. A brief history of BELLE. Hum Exper Toxicol 2010 ; 29: 247-248.
9. Calabrese EJ Getting the dose response wrong. Why hormesis became marginalized and the threshold model accepted. Arch Toxicol 2009 ; 83: 227-247.
10. Calabrese EJ The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment. Arch Toxicol 2009 ; 83: 203-225.
11. Calabrese EJ, Baldwin LA Toxicology rethinks its central belief-hormesis demands a reappraisal of the way risks are assessed. Nature 2003 ; 421: 691-692.
12. Calabrese EJ, Baldwin LA The hormetic dose response model is more common than the threshold model in toxicology. Toxicol Sci 2003 ; 71: 246-250.
13. Calabrese EJ, Baldwin LA Hormesis: U-shaped dose-response and their centrality in toxicology. Trends Pharmacol Sci 2001 ; 22: 285-291.
14. Calabrese EJ, Blain R. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. Toxicol Appl Pharmacol 2005 ; 202: 289-301.
15. Calabrese EJ, Baldwin LA Hormesis: the dose-response revolution. Ann Rev Pharmacol Toxicol 2003 c; 43: 175-197.
16. Calabrese EJ, Baldwin LA The frequency of U-shaped dose responses in the toxicological literature. Toxicol Sci 2001 ; 62: 330-338.
17. Calabrese EJ, Hoffmann GR, Stanek EJ, and Nascarella MA Hormesis in high-throughput screening of antibacterial compounds in E. coli. Hum Exp Toxicol 2010 ; 29: 667-677.
18. Calabrese EJ, Stanek EJ 3rd, Nascarella MA, and Hoffmann GR Hormesis predicts low-dose responses better than threshold models. Int J Toxicol 2008 ; 27: 369-378.
19. Calabrese EJ, Staudenmayer JW, Stanek EJ, and Hoffmann GR Hormesis outperforms threshold model in NCI anti-tumor drug screening data. Toxicol Sci 2006 ; 94: 368-378.